Brief: IVERIC Bio To Present Top-Line Results For Avacincaptad Pegol From Phase 3 Gather2 Clinical Trial In Geographic Atrophy At Aao 2022 Annual Meeting
27/09/2022 13:16
Sept 27 (Reuters) - Iveric Bio Inc ISEE.O :
* IVERIC BIO TO PRESENT TOP-LINE RESULTS FOR AVACINCAPTAD
PEGOL
FROM PHASE 3 GATHER2 CLINICAL TRIAL IN GEOGRAPHIC ATROPHY AT AAO
2022 ANNUAL MEETING
Source text for Eikon: ID:nBw12byXTa
Further company coverage: ISEE.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on IVERIC bio
See all newsBrief: Astellas Pharma Inc - Astellas Completes Acquisition Of Iveric Bio
Analysis: Amgen's antitrust woes spur wider pharmaceutical deal fears
Iveric Bio Inc Reports Results For The Quarter Ended In March: Earnings Summary
The end of cheap credit could hurry Japanese M&A
U.S. STOCKS ON THE MOVE-US banks, Biomea Fusion, Tutor Perini